Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to collect plasma by apheresis from patients who have recovered from Severe Acute Respiratory Syndrome (SARS). This plasma will be processed into a SARS-antibody enriched intravenous immune globulin (IVIG) product. This product will then be available for use in a clinical trial if a SARS epidemic recurs.

Potentially eligible participants are people between 18 and 56 years of age who have recovered from SARS. Potential participants will undergo three sequential screenings to determine their eligibility for this study. Eligible participants will then be scheduled for plasmapheresis. After apheresis, additional testing will be performed on a sample of the source plasma. Once the sample has been tested and cleared, the source plasma will be shipped to the United States to the storage facility and finally to the site of manufacturing of the IVIG product. Participants may donate plasma again after 14 days.

The study will not have a direct benefit for participants. However, participation may help develop a treatment that could be useful to other people who become infected with SARS.


Clinical Trial Description

Beginning in February 2003, there was an outbreak with a novel coronavirus causing an atypical pneumonia, subsequently referred to as Severe Acute Respiratory Syndrome (SARS). This syndrome is associated with a high mortality rate and has no proven treatment. There is, however, some evidence that treatment with convalescent plasma was beneficial.

The primary purpose of this protocol is to collect plasma by apheresis from patients that recovered from SARS, and process this plasma into a high titer anti-SARS intravenous immune globulin (IVIG). This will be a collaboration between the National Institute of Allergy and Infectious Diseases and the Chinese University of Hong Kong. Cangene Corporation has been contracted to manufacture the collected plasma in the United States (U.S.) into an IVIG product, which can then be used for pre-clinical efficacy studies under an IND in a clinical trial if SARS recurs. It is intended that the treatment trial would be conducted in Hong Kong and/or the U.S., as well as any other place the disease recurs. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00342524
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact
Status Completed
Phase N/A
Start date July 6, 2005
Completion date February 8, 2007

See also
  Status Clinical Trial Phase
Completed NCT04542915 - COVID-19-Related Health and Practices Among Dental Hygienists
Completed NCT04515147 - A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19 Phase 2
Recruiting NCT04480333 - Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831 Phase 1
Completed NCT04402957 - LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) Phase 2
Withdrawn NCT04838847 - A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19 Phase 3
Not yet recruiting NCT04386070 - Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 Phase 3
Withdrawn NCT00073086 - Evaluation and Treatment of Severe Acute Respiratory Syndrome (SARS) N/A
Active, not recruiting NCT04527432 - COVID-19 Health Professional Impact Study N/A
Completed NCT00215826 - Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers Phase 2
Completed NCT04366934 - Study of the Pathogenesis of Olfactory Disorders in COVID-19
Completed NCT04376684 - Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease Phase 2
Completed NCT04402060 - A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 Phase 1/Phase 2
Completed NCT04395144 - COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss N/A
Completed NCT04357730 - Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection Phase 2
Completed NCT04425213 - Obesity and Mortality of Critically Ill Patients With COVID-19
Completed NCT04425863 - Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19
Completed NCT06287554 - Effect of Early Implementation of Prone Positioning
Completed NCT04328129 - Household Transmission Investigation Study for COVID-19 in Tropical Regions N/A
Completed NCT04602351 - Communication in ICU During COVID-19
Completed NCT03225807 - Implementation of Lung Protective Ventilation in Patients With Acute Respiratory Failure